Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Zacks News
Abbott (ABT) Nutrition Shows Robust Momentum Amid Pandemic
by Zacks Equity Research
Within Medical Device, Abbott (ABT) Diabetes Care business has been in the limelight for developments in its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and robust product portfolio. However, high debt level remains a woe.
The Zacks Analyst Blog Highlights: Abbott Laboratories, AstraZeneca, Booking, Vertex Pharmaceuticals and Yum China
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Laboratories, AstraZeneca, Booking, Vertex Pharmaceuticals and Yum China
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $120.49 in the latest trading session, marking a -0.81% move from the prior day.
Top Analyst Reports for Abbott, AstraZeneca & Booking Holdings
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), AstraZeneca (AZN), and Booking Holdings (BKNG).
Here's Why You Should Hold on to Tandem Diabetes (TNDM) Stock
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) on robust pump sales and shipments.
New Study Favors Masimo's (MASI) Pulse Oximetry to Screen CCHD
by Zacks Equity Research
The latest study highlights the efficacy of using Masimo's (MASI) SET pulse oximetry in screening CCHD in newborns.
Here's Why You Should Retain Glaukos (GKOS) Stock Right Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.
PRA Health (PRAH) Unveils Toolkit for Rare Disease Patients
by Zacks Equity Research
PRA Health (PRAH) launches patient-focused toolkit to lower the burden on patients with rare diseases to participate in clinical research.
Intersect ENT (XENT) Hit by Low ENT Office Visits Amid COVID-19
by Zacks Equity Research
Intersect ENT (XENT) is worried about the first-quarter performance as well on the significant surge in COVID-19 case rates.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from robust payment accuracy business and strategic deals. However, intense competition remains a woe.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD), owing to its potential in digital health and consistent high demand for its critical care products.
Boston Scientific's (BSX) TheraSphere Approved by FDA for HCC
by Zacks Equity Research
Boston Scientific's (BSX) TheraSphere therapy to be made accessible to more patients following the FDA's clearance.
IDEXX (IDXX) CAG Placement Grows Sequentially Amid COVID-19 Woes
by Zacks Equity Research
IDEXX's (IDXX) Global Reference Lab revenues are growing organically in the United States and in international markets.
Veeva (VEEV) Application Completes Consent for First Patient (Revised)
by Zacks Equity Research
With this latest development, Veeva (VEEV) is likely to strengthen its portfolio of cloud-based offerings.
4 Stocks in Focus as Diabetes Sector Grows Amid Pandemic
by Debanjana Dey
Here are a few diabetes-centric MedTech stocks, ABT, NVO, MDT, PODD and TNDM, which investors can focus on to reap profits in the new normal.
Veeva (VEEV) Application Completes Consent for First Patient
by Zacks Equity Research
With this latest development, Veeva (VEEV) is likely to strengthen its portfolio of cloud-based offerings.
Zimmer Biomet (ZBH) Shows Strong Core Growth Amid Weak EMEA
by Zacks Equity Research
For Zimmer Biomet (ZBH), the spin-off is an important step forward to its transition into a more streamlined business with a focus on more optimized resource allocation.
Medtronic (MDT) Gets FDA Nod for Revised Neuromodulation Labeling
by Zacks Equity Research
This latest development is expected to contribute to Medtronic's (MDT) pain therapy business in the coming months.
Why You Should Hold on to Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and robust adoption of products.
Masimo's (MASI) EMMA Favored by New Study for Children
by Zacks Equity Research
The latest study highlights the importance of Masimo's (MASI) EMMA for children with tracheostomy, both in home-care settings and outpatient departments.
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $117.62, marking a -0.51% move from the previous day.
CVS Health (CVS) Extends COVID-19 Testing in Massachusetts
by Zacks Equity Research
CVS Heath's (CVS) antibody testing to be available in nearly 60 MinuteClinic locations and cost $38.
NuVasive (NUVA), ISSGF Expand Tie-Up With Launch of 2 Studies
by Zacks Equity Research
NuVasive (NUVA) extends its long-term partnership with ISSGF and initiates additional clinical studies to transform the future of spine care.
HealthEquity (HQY) Q4 Earnings, Revenues Beat Estimates
by Zacks Equity Research
HealthEquity (HQY) delivers solid growth in HSAs and custodial assets in the fiscal fourth quarter.